What science can do金沙手机app平台

Annual Report and Form 20-F
Information 2018
金沙官网

01

金沙官网

This Annual Report quick-阅读 provides top-level 资讯rmation on our business and the progress we have made in 2018 in pushing the boundaries of science to deliver life-changing medicines and demonstrating what science can do.



Science can


Science can


Science can


Science can


Science can


02

金沙官网


In 2018, under the leadership of Pascal Soriot, and together with the entire talented AstraZeneca 团队, we delivered on our promise and returned a reinvigorated AstraZeneca to 产品介绍 Sales growth. We succeeded because we have been true to our Value of following the science. We also succeeded because we put patients first.

Leif Johansson, Chairman

I am pleased to report that, in 2018, after the previous six years in which revenues had fallen by 更多 than one third, we turned the corner and returned to 产品介绍 Sales growth, driven by a new generation of medicines from our therapy areas.

Pascal Soriot, Chief Executive Officer

03

金沙官网

2018 marked our return to 产品介绍 Sales growth with strong performance from Growth Platforms and New Medicines 更多 than offsetting the continued impact from patent expiries.


金沙手机app平台


Total Revenue*
金沙手机app平台

$22.1bn金沙手机app平台


Net cash flow from operating activities
Down 27% at actual rate of exchange to $2,618 million




金沙手机app平台

$2.6bn金沙手机app平台

// Denotes a scale break. All bar chart scales start from zero. We use a scale break where charts of a different magnitude, but the same unit of measurement, are presented alongside each other.

*Total Revenue consists of Product Sales and Externalisation Revenue.

 

金沙手机app平台


Reported operating profit
Down 8% at actual rate of exchange to $3,387 million (down 7% at CER)
金沙手机app平台

$3.4bn金沙手机app平台


Core operating profit
Down 17% at actual rate of exchange to $5,672 million (down 17% at CER)
金沙手机app平台

$5.7bn金沙手机app平台

金沙手机app平台


Reported EPS
Down 28% at actual rate of exchange to $1.70 (down 29% at CER)
金沙手机app平台

$1.70金沙手机app平台


Core EPS
Down 19% at actual rate of exchange to $3.46 (down 19% at CER)
金沙手机app平台

$3.46金沙手机app平台



04

金沙官网

We are a global science-led business delivering medicines to patients through innovative science and excellence in development and commercialisation.


金沙官网


Total Product Sales
金沙官网

$21,049m金沙官网

2017: $20,152m
2016: $21,319m
金沙手机app平台


金沙官网



金沙官网




金沙官网


金沙手机app平台

金沙手机app平台

金沙手机app平台

金沙手机app平台

金沙手机app平台

金沙手机app平台


金沙官网



金沙官网

Broadening access to healthcare

 



金沙官网

Furthering ethics and transparency

 



金沙官网

Protecting the environment

 




金沙官网



金沙官网

$0.90金沙手机app平台

Pence: 68.4
SEK: 7.92
Payment date: 10 September 2018
金沙手机app平台


金沙官网

$1.90金沙手机app平台

Pence:146.8
SEK: 17.46
Payment date: 27 March 2019
金沙手机app平台


金沙官网

$2.80金沙手机app平台

Pence: 215.2
SEK: 25.38

金沙手机app平台


05

金沙官网

We announced our strategy for returning to growth in 2013. The first phase in our journey was focused on rebuilding our pipeline. The second stage was crucial as we drove our Growth Platforms forward, continued to launch new medicines and made them available to patients. We returned to Product Sales growth in 2018 and, as we look ahead to 2020 and beyond, continued investment in our product launches and pipeline will keep us on track to deliver sustainable growth in line with our targets.

We are a ‘pure-play’, global, science-led pharmaceutical company. We are focused on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of unmet medical need in three main therapy areas: Oncology; Cardiovascular, Renal and Metabolism (CVRM); and Respiratory. In 2018, our strategic priorities were focused under the three pillars listed below.



2018 Highlights


2018 Highlights


2018 Highlights


金沙官网